Sleep Apnea Symptoms: Drugs That Cause or Treat It

What Sleep Apnea Symptoms Look Like and Why Drugs Matter

Sleep apnea symptoms include loud snoring, witnessed breathing pauses during sleep, gasping or choking episodes, morning headaches, and excessive daytime sleepiness. These are cardinal signs. The condition divides into obstructive sleep apnea (OSA), central sleep apnea (CSA), and mixed forms, each with distinct pharmacologic triggers and treatment targets.

A 2019 Lancet Respiratory Medicine analysis estimated that 936 million adults aged 30 to 69 have mild-to-severe OSA globally, with 425 million experiencing moderate-to-severe disease [1]. Medications affect airway muscle tone, central respiratory drive, body weight, and fluid distribution. All four pathways influence whether a patient develops new symptoms or sees existing ones improve. The American Academy of Sleep Medicine (AASM) 2024 clinical practice guideline on pharmacotherapy for OSA acknowledged that "weight management pharmacotherapy should be considered as an adjunct to comprehensive sleep apnea treatment in adults with OSA and obesity" [2]. That statement marked a turning point in how clinicians think about drug-based approaches to a condition long treated almost exclusively with devices.

Understanding which drugs sit on each side of the equation gives patients and prescribers a concrete framework for medication reviews. A single drug change can be the difference between 30 apnea events per hour and 12.

Drugs That Cause or Worsen Sleep Apnea Symptoms

Certain medication classes reliably increase the frequency and severity of obstructive and central apnea events. Recognizing these is a safety priority for any patient with known or suspected sleep-disordered breathing.

Opioids

Chronic opioid therapy is the single most common pharmacologic cause of central sleep apnea. A 2014 systematic review published in Chest found CSA prevalence ranging from 24% to 75% among patients on long-term opioids, with higher morphine milligram equivalents (MME) correlating with higher AHI [3]. Opioids suppress medullary respiratory centers, blunt the hypercapnic ventilatory response, and produce irregular breathing patterns including ataxic breathing and sustained hypoxemia. Methadone carries particular risk; one study found CSA in 30% of methadone maintenance patients at doses above 100 mg daily [3]. The effect is dose-dependent. Patients on <100 MME daily had a CSA prevalence roughly half that of patients above that threshold.

Benzodiazepines and Sedative-Hypnotics

Benzodiazepines reduce upper airway muscle tone through GABA-A receptor potentiation. A 2019 meta-analysis in the Journal of Clinical Sleep Medicine found that benzodiazepine use was associated with a 1.5-fold increased risk of incident OSA diagnosis [4]. Diazepam, lorazepam, and clonazepam all prolong apnea event duration and lower the oxygen desaturation nadir. The combination of opioids and benzodiazepines is especially dangerous. The FDA added a black box warning in 2016 specifically citing respiratory depression risk. Non-benzodiazepine hypnotics (zolpidem, eszopiclone) carry a smaller but non-negligible effect on airway collapsibility [4].

Muscle Relaxants and Baclofen

Baclofen, a GABA-B receptor agonist used for spasticity, depresses central respiratory drive at doses above 40 mg daily. Case reports document new-onset CSA in patients started on baclofen for chronic pain or multiple sclerosis [5]. Tizanidine and cyclobenzaprine have less respiratory effect but still reduce airway muscle tone enough to worsen OSA in patients with borderline anatomy.

Alcohol

Alcohol is not a prescription drug, but it deserves mention because it interacts with every class above. A study in the American Journal of Medicine demonstrated that alcohol consumption within 2 to 3 hours of sleep increases apnea-hypopnea events by approximately 25% in otherwise mild OSA patients [6]. It relaxes pharyngeal dilator muscles and raises the arousal threshold, meaning the brain takes longer to respond to airway obstruction.

Testosterone Replacement Therapy

Exogenous testosterone has been associated with worsened OSA in some men. A 2014 randomized controlled trial published in the New England Journal of Medicine (testosterone in older men with mobility limitations) found that testosterone-treated men had a higher rate of respiratory-related adverse events [7]. The Endocrine Society's 2018 guideline recommends screening for OSA symptoms before initiating testosterone therapy and monitoring during treatment [8]. The mechanism appears related to testosterone's effect on upper airway collapsibility and possibly on central ventilatory control. Not every patient worsens. Risk is highest in men with pre-existing anatomic narrowing or obesity.

Drugs That Treat Sleep Apnea: Reducing Apnea Events

Pharmacotherapy for the apnea events themselves is a newer frontier. CPAP remains first-line per AASM guidelines, but adherence hovers around 50% at one year. Drug options now exist for patients who cannot tolerate or refuse positive airway pressure.

Tirzepatide (Zepbound) for Obesity-Related OSA

Tirzepatide, a dual GIP/GLP-1 receptor agonist, received FDA approval in December 2024 for moderate-to-severe OSA in adults with obesity, making it the first drug approved specifically for OSA [9]. The approval rested on two phase 3 SURMOUNT-OSA trials. In SURMOUNT-OSA 1 (N=234, patients not using CPAP), tirzepatide 10 mg or 15 mg reduced AHI by a mean of 25.3 events per hour (approximately 55.0% reduction) compared with 5.3 events per hour for placebo at 52 weeks. SURMOUNT-OSA 2 (N=235, patients using CPAP) showed similar reductions: mean AHI decrease of 30.4 events per hour with tirzepatide versus 6.0 with placebo [10].

Body weight decreased by 18.1% in the tirzepatide arm of SURMOUNT-OSA 1 [10]. Dr. Atul Malhotra, chief of pulmonary, critical care, and sleep medicine at UC San Diego, stated: "The magnitude of AHI reduction with tirzepatide was larger than what we have previously seen with any weight loss intervention for sleep apnea" [10].

Dosing follows the obesity indication: subcutaneous injection once weekly, titrated from 2.5 mg to a maximum of 15 mg over 20 weeks. Gastrointestinal side effects (nausea, diarrhea, constipation) are the primary tolerability concern.

Semaglutide and Other GLP-1 Receptor Agonists

Liraglutide 3.0 mg (Saxenda) was studied in the SCALE Sleep Apnea trial (N=359), where it reduced AHI by 12.2 events per hour versus 6.1 for placebo over 32 weeks, accompanied by 5.7% weight loss [11]. Semaglutide 2.4 mg (Wegovy) has not completed a dedicated OSA trial as of May 2026, but the STEP-1 trial (N=1,961) produced 14.9% mean body weight reduction at 68 weeks [12], and post-hoc analyses of GLP-1 data suggest AHI reductions proportional to weight lost. Every 1% of body weight loss corresponds to roughly a 1.5% decrease in AHI based on longitudinal cohort data [13].

Acetazolamide for Central and High-Altitude Sleep Apnea

Acetazolamide, a carbonic anhydrase inhibitor, has been used for decades to treat CSA and altitude-related periodic breathing. It works by inducing a mild metabolic acidosis that stimulates ventilation and narrows the gap between the eupneic CO2 level and the apneic threshold. A randomized trial in Annals of Internal Medicine (N=12 crossover) demonstrated a 47% reduction in central apnea index with acetazolamide 250 mg four times daily [14]. Typical dosing ranges from 250 mg to 500 mg at bedtime. Side effects include paresthesias, metabolic acidosis, and kidney stone risk with long-term use.

Emerging Agents: AD109 (Arousal Threshold Targeted Therapy)

AD109, a combination of atomoxetine (a norepinephrine reuptake inhibitor) and aroxybutynin (an antimuscarinic), targets two endotypic traits of OSA: inadequate pharyngeal dilator muscle activity and low arousal threshold. Phase 2 data (N=211) published in 2024 showed a 22.5 event per hour reduction in AHI versus a 10.5 event reduction with placebo [15]. Phase 3 trials are ongoing. This approach represents a shift toward endotype-directed pharmacotherapy, where drug selection matches the patient's specific pathophysiologic mechanism rather than treating OSA as a single disease.

Drugs That Treat Residual Sleepiness in Sleep Apnea

Even with adequate CPAP use, 12% to 65% of OSA patients report persistent excessive daytime sleepiness (EDS). Three FDA-approved medications address this symptom directly.

Solriamfetol (Sunosi)

Solriamfetol is a dopamine and norepinephrine reuptake inhibitor approved in 2019 for EDS associated with OSA or narcolepsy. The TONES 3 trial (N=476) randomized OSA patients with residual sleepiness despite primary OSA therapy to solriamfetol 37.5 mg, 75 mg, 150 mg, or 300 mg daily versus placebo [16]. At 12 weeks, the 150 mg dose reduced Epworth Sleepiness Scale (ESS) scores by 4.7 points more than placebo. The 300 mg dose showed a 22.4% improvement in sleep latency on the Maintenance of Wakefulness Test (MWT). Starting dose is 37.5 mg once daily, titrated to 75 mg or 150 mg. The maximum recommended dose is 150 mg for OSA. Common side effects include headache (9.4%), nausea (6.1%), decreased appetite, and anxiety [16]. Blood pressure and heart rate should be monitored, as increases of 1 to 3 mmHg systolic and 1 to 2 bpm have been observed.

Pitolisant (Wakix)

Pitolisant is a first-in-class histamine H3 receptor inverse agonist. By blocking presynaptic H3 autoreceptors, it increases histaminergic neurotransmission in wake-promoting brain circuits. The HAROSA I trial (N=268) demonstrated that pitolisant 20 mg daily reduced ESS scores by 2.8 points more than placebo in OSA patients with residual EDS [17]. It is not a controlled substance, which distinguishes it from traditional stimulants. The FDA approved it for OSA-related EDS in 2020 at doses of 17.8 mg to 35.6 mg daily. QTc prolongation is a labeled risk; baseline ECG is recommended.

Modafinil and Armodafinil

Modafinil (200 mg to 400 mg daily) and armodafinil (150 mg to 250 mg daily) were the first agents approved for residual EDS in treated OSA. A 2003 randomized trial in Chest (N=157) showed modafinil 400 mg improved ESS by 4.0 points versus 1.2 points with placebo over 4 weeks [18]. They are Schedule IV controlled substances. AASM guidelines note these are appropriate only when CPAP adherence has been optimized and sleepiness persists [2]. Dr. Shalini Paruthi, an AASM spokesperson, has noted: "Pharmacotherapy for sleepiness should never replace the primary treatment of the underlying airway obstruction. CPAP or an oral appliance must remain the foundation" [2].

How to Know When Your Medications Are Affecting Sleep Apnea

Medication-induced sleep apnea can be subtle. Three patterns should prompt evaluation.

First, new or worsening snoring within weeks of starting an opioid, benzodiazepine, or muscle relaxant. Second, persistent morning headaches or unexplained daytime fatigue after a dose increase of any CNS depressant. Third, a bed partner reporting new breathing pauses.

The screening step is straightforward: a home sleep apnea test (HSAT) or in-lab polysomnography (PSG) establishes the AHI. An AHI of 5 to 14 is mild, 15 to 29 is moderate, and 30 or above is severe [19]. If a medication is suspected, the clinician compares AHI before and after dose adjustment or drug discontinuation. Opioid-induced CSA sometimes resolves within 1 to 3 months of tapering, though structural OSA coexisting with CSA may not [3].

A useful clinical checkpoint: any patient starting chronic opioid therapy at <60 MME daily should be screened with the STOP-Bang questionnaire. Patients scoring 5 or higher warrant polysomnography regardless of symptoms [19].

Weight-Loss Pharmacotherapy as an Upstream Treatment

Obesity is the strongest modifiable risk factor for OSA. About 60% to 70% of OSA patients are overweight or obese, and the Wisconsin Sleep Cohort Study showed that a 10% weight gain predicted a 32% increase in AHI, while a 10% weight loss predicted a 26% decrease [13].

The pharmacologic weight-loss arsenal now includes semaglutide 2.4 mg (Wegovy), tirzepatide (Zepbound), and phentermine-topiramate (Qsymia). Each produces enough weight loss to meaningfully reduce AHI. Phentermine-topiramate at the 15 mg/92 mg dose produced 9.8% weight loss at 56 weeks in the SEQUEL trial (N=676) [20]. Topiramate also has mild carbonic anhydrase inhibitor activity, potentially contributing a small direct ventilatory stimulant effect.

For patients with BMI ≥30 and moderate-to-severe OSA who refuse or fail CPAP, pharmacologic weight management is not optional. It is a treatment with level 1 evidence for AHI reduction. The 2024 AASM guideline explicitly states this [2].

Building a Medication Review for Sleep Apnea Patients

A structured medication review should catalog every CNS depressant, opioid, muscle relaxant, and sedating antihistamine in the patient's regimen. Rank each by respiratory depression risk.

Step one: identify all opioids and convert to MME. If total daily MME exceeds 50, polysomnography is indicated regardless of symptom burden. Step two: identify all benzodiazepines and Z-drugs. Consider taper or switch to trazodone or suvorexant for insomnia (orexin receptor antagonists have not shown OSA worsening in current data) [21]. Step three: check testosterone dose if applicable. Men on TRT with new snoring or witnessed apneas need a sleep study.

On the treatment side, confirm CPAP adherence data (downloaded from the device). If average nightly use is below 4 hours and the patient reports persistent sleepiness, solriamfetol 75 mg to 150 mg daily or pitolisant 17.8 mg daily is appropriate. For patients with BMI ≥30, add a GLP-1 receptor agonist or tirzepatide with the explicit goal of AHI reduction alongside weight management.

Document every change. Sleep apnea is a condition where small pharmacologic adjustments produce measurable, polysomnography-confirmed outcomes within 8 to 12 weeks.